Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
T414465-25mg | 25mg | In stock | $244.90 | |
T414465-100mg | 100mg | In stock | $815.90 | |
T414465-250mg | 250mg | In stock | $1,414.90 | |
T414465-1g | 1g | In stock | $5,094.90 |
AhR Agonists
Synonyms | 5-((1E)-2-PHENYLETHEN-1-YL)-2-(PROPAN-2-YL)BENZENE-1,3-DIOL | Tapinarof (USAN) | 5-[(1E)-2-Phenylethen-1-yl]-2-(propan-2-yl)benzene-1,3-diol | GTPL9686 | AKOS025296109 | s9700 | TAPINAROF [INN] | BCP13569 | Sinefunginum [INN-Latin] | 2-Isopropyl-5-styrylb |
---|---|
Specifications & Purity | Moligand™, ≥99% |
Biochemical and Physiological Mechanisms | Tapinarof (GSK2894512, Benvitimod, WBI 1001, DHPS, DMVT 505) is a natural agonist of aryl hydrocarbon receptor (AhR) and induces nuclear translocation of AhR in immortalized keratinocytes (HaCaT) with EC50 of 0.16 nM. Tapinarof induces cellular apoptosis |
Storage Temp | Protected from light,Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Aryl hydrocarbon receptor agonist |
Product Description | Information Tapinarof Tapinarof (GSK2894512, Benvitimod, WBI 1001, DHPS, DMVT 505) is a natural agonist of aryl hydrocarbon receptor (AhR) and induces nuclear translocation of AhR in immortalized keratinocytes (HaCaT) with EC50 of 0.16 nM. Tapinarof induces cellular apoptosis in CD4+ T cells in a dosedependent manner with IC50 of 5.2 μM. Targets AhR (in immortalized keratinocytes); apoptosis (in CD4+ T cells) 0.16 nM(EC50); 5.2 μM In vitro Tapinarof binds and activates AhR in multiple cell types, including cells of the target tissue –human skin. In addition, tapinarof moderates proinflammatory cytokine expression in stimulated peripheral blood CD4+ T cells and ex vivo human skin, and impacts barrier gene expression in primary human keratinocytes; both of these processes are likely to be downstream of AhR activation based on current evidence. In vivo The anti-inflammatory properties of tapinarof derive from AhR agonism is conclusively demonstrated using the mouse model of imiquimod-induced psoriasiform skin lesions. Topical treatment of AhR-sufficient mice with tapinarof leads to compound-driven reductions in erythema, epidermal thickening and tissue cytokine levels. In contrast, tapinarof has no impact on imiquimod-induced skin inflammation in AhR-deficient mice. Cell Research(from reference) Cell lines:HaCaT cells Concentrations:0.01 pM - 1 μM Incubation Time:30 min |
ALogP | 4.526 |
---|---|
HBD Count | 2 |
Rotatable Bond | 3 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 5-[(E)-2-phenylethenyl]-2-propan-2-ylbenzene-1,3-diol |
---|---|
INCHI | InChI=1S/C17H18O2/c1-12(2)17-15(18)10-14(11-16(17)19)9-8-13-6-4-3-5-7-13/h3-12,18-19H,1-2H3/b9-8+ |
InChi Key | ZISJNXNHJRQYJO-CMDGGOBGSA-N |
Canonical SMILES | CC(C)C1=C(C=C(C=C1O)C=CC2=CC=CC=C2)O |
Isomeric SMILES | CC(C)C1=C(C=C(C=C1O)/C=C/C2=CC=CC=C2)O |
PubChem CID | 6439522 |
Molecular Weight | 254.32 |
PubChem CID | 6439522 |
---|---|
ChEMBL Ligand | CHEMBL259571 |
CAS Registry No. | 79338-84-4 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
F23061212 | Certificate of Analysis | Apr 17, 2023 | T414465 |
F23061244 | Certificate of Analysis | Apr 17, 2023 | T414465 |
F23061305 | Certificate of Analysis | Apr 17, 2023 | T414465 |
F23061329 | Certificate of Analysis | Apr 17, 2023 | T414465 |
F23061339 | Certificate of Analysis | Apr 17, 2023 | T414465 |
F23061400 | Certificate of Analysis | Apr 17, 2023 | T414465 |
F23061413 | Certificate of Analysis | Apr 17, 2023 | T414465 |
F23061415 | Certificate of Analysis | Apr 17, 2023 | T414465 |
Solubility | Solubility (25°C) In vitro DMSO: 51 mg/mL (200.53 mM); Ethanol: 51 mg/mL (200.53 mM); Water: Insoluble; |
---|---|
Sensitivity | Light sensitive |
DMSO(mg / mL) Max Solubility | 51 |
DMSO(mM) Max Solubility | 200.534759358289 |
Water(mg / mL) Max Solubility | <1 |
Pictogram(s) | GHS09 |
---|---|
Signal | Warning |
Hazard Statements | H400:Very toxic to aquatic life H410:Very toxic to aquatic life with long lasting effects |
Precautionary Statements | P273:Avoid release to the environment. P501:Dispose of contents/container to ... P391:Collect spillage. |
Starting at $241.90
1. Bissonnette R, Bolduc C, Maari C, Nigen S, Webster JM, Tang L, Lyle M. (2012) Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial.. J Eur Acad Dermatol Venereol, 26 (12): (1516-21). [PMID:22077962] [10.1021/op500134e] |
2. Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, Coquery CM, Neil J, Pryor WM, Mayhew D et al.. (2017) Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans.. J Invest Dermatol, 137 (10): (2110-2119). [PMID:28595996] [10.1021/op500134e] |
3. Lebwohl MG, Stein Gold L, Strober B, Papp KA, Armstrong AW, Bagel J, Kircik L, Ehst B, Hong HC, Soung J et al.. (2021) Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.. N Engl J Med, 385 (24): (2219-2229). [PMID:34879448] [10.1021/op500134e] |